within Pharmacolibrary.Drugs.ATC.G;

model G03AA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 5.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03AA08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Medroxyprogesterone and ethinylestradiol is a combined oral contraceptive containing the progestin medroxyprogesterone acetate and the estrogen ethinylestradiol. This combination was previously used for hormonal contraception and regulation of menstrual disorders. Currently, it is not widely used or approved in most countries, having been largely replaced by other contraceptive combinations.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult women based on published pharmacokinetics of individual components (medroxyprogesterone acetate and ethinylestradiol) as no specific studies of the combination were identified.</p><h4>References</h4><ol><li><p>Kapitza, C, et al., &amp; Flint, A (2015). Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. <i>Journal of clinical pharmacology</i> 55(5) 497–504. DOI:<a href=&quot;https://doi.org/10.1002/jcph.443&quot;>10.1002/jcph.443</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25475122/&quot;>https://pubmed.ncbi.nlm.nih.gov/25475122</a></p></li><li><p>Wang, X, et al., &amp; Malhotra, BK (2024). Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. <i>European journal of drug metabolism and pharmacokinetics</i> 49(3) 367–381. DOI:<a href=&quot;https://doi.org/10.1007/s13318-024-00893-5&quot;>10.1007/s13318-024-00893-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38554232/&quot;>https://pubmed.ncbi.nlm.nih.gov/38554232</a></p></li><li><p>Burness, CB (2015). Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique(®)): A Review of Its Use as an Oral Contraceptive. <i>Drugs</i> 75(9) 1019–1026. DOI:<a href=&quot;https://doi.org/10.1007/s40265-015-0407-9&quot;>10.1007/s40265-015-0407-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26017303/&quot;>https://pubmed.ncbi.nlm.nih.gov/26017303</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03AA08;
